[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607166":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":119,"collaborators":25,"id":122,"slug":25,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":123,"sex":129,"minAge":130,"maxAge":25,"enrollmentInfo":131,"targetDuration":25,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":147,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"The Second Hospital of Anhui Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intra-arterial Thrombolysis plus Best Medical Treatment","EXPERIMENTAL","Patients in this group will receive intra-arterial thrombolysis plus best medical treatment.",[13,14],"Procedure: Intra-arterial Thrombolysis","Drug: Best Medical Treatment",{"label":16,"type":6,"description":17,"interventionNames":18},"Best Medical Treatment","Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Intra-arterial Thrombolysis","rhTNK-tPA（Tenecteplase）dose: 0.4 - 1.2mg\u002Fmin, maximum dose: 16mg. Patients who have not received IVT are recommended to initiate intra-arterial administration at a rate of 0.8 mg\u002Fmin, whereas those who have received IVT are recommended to receive 0.4 mg\u002Fmin. The infusion rate may be dynamically adjusted by the operator according to intra-procedural circumstances, with a maximum rate not exceeding 1.2 mg\u002Fmin.",[9],null,{"type":27,"name":16,"description":17,"armGroupLabels":28,"otherNames":25},"DRUG",[16,9],[30],{"name":31,"affiliation":5,"role":32},"Qi Li, professor","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","+8618623511778","qili_md@126.com",[39,56,66,78,91,105],{"facility":40,"status":41,"city":42,"state":43,"zip":25,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Fu Yang People's Hospital","RECRUITING","Fuyang","Anhui","China",{"type":46,"coordinates":47},"Point",[48,49],115.81667,32.9,{"lat":49,"lon":48},[52,55],{"name":53,"role":35,"phone":54,"phoneExt":25,"email":25},"Juluo Chen","0558-3010999",{"name":53,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":57,"status":41,"city":42,"state":43,"zip":25,"country":44,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"Lin Quan People's Hospital",{"type":46,"coordinates":59},[48,49],{"lat":49,"lon":48},[62,65],{"name":63,"role":35,"phone":64,"phoneExt":25,"email":25},"Susheng Long","0558-6403761",{"name":63,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":67,"status":41,"city":68,"state":43,"zip":69,"country":44,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"The Second (Affiliated) Hospital of Anhui Medical University","Hefei","230031",{"type":46,"coordinates":71},[72,73],117.28083,31.86389,{"lat":73,"lon":72},[76,77],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":79,"status":41,"city":80,"state":43,"zip":25,"country":44,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Shucheng People's Hospital","Lu'an",{"type":46,"coordinates":82},[83,84],116.51688,31.73561,{"lat":84,"lon":83},[87,90],{"name":88,"role":35,"phone":89,"phoneExt":25,"email":25},"Jianshang Wen","0564-8621570",{"name":88,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":92,"status":41,"city":93,"state":94,"zip":25,"country":44,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"LiuZhou Worker's Hospital","Liuzhou","Guangxi",{"type":46,"coordinates":96},[97,98],109.40698,24.32405,{"lat":98,"lon":97},[101,104],{"name":102,"role":35,"phone":103,"phoneExt":25,"email":25},"Xianfu Lu","0772-3815345",{"name":102,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":106,"status":41,"city":107,"state":108,"zip":25,"country":44,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Lishui Central Hospital","Lishui","Zhejiang",{"type":46,"coordinates":110},[111,112],119.91029,28.46042,{"lat":112,"lon":111},[115,118],{"name":116,"role":35,"phone":117,"phoneExt":25,"email":25},"Xiao Peng","05782285888",{"name":116,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":32,"investigatorFullName":120,"investigatorTitle":121,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Qi Li","Professor","100607166",false,"NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason","ALL","18 Years",{"count":132,"type":133},282,"ESTIMATED","INTERVENTIONAL",[136],"NA","Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[139,140,141,142,143,144,145,146],"Stroke","Cerebrovascular Disorders","Brain Diseases","Nervous System Diseases","Vascular Diseases","Ischemic Stroke","Infarction","Medium Vessel Occlusion",[148,149,139,150,151],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":154,"type":155},"2026-04-16","ACTUAL",{"date":157,"type":155},"2026-01-06",{"date":159,"type":133},"2030-05-01",{"name":5,"class":6},6]